India Gastrointestinal Drugs Market Analysis Report 2022 to 2030

India Gastrointestinal Drugs Market Analysis

$ 3999

This report presents a strategic analysis of the India Gastrointestinal Drugs Market Analysis and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the India Gastrointestinal Drugs Market Analysis, offering unmatched value, accuracy, and expert insights.

ID: IN10INPH106 CATEGORY: Pharmaceuticals GEOGRAPHY: India

Buy Now

India Gastrointestinal Drugs Executive Summary

The market for gastrointestinal drugs consists of sales of GI drugs made by organizations, sole proprietorships, and partnerships that treat gastrointestinal conditions like ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. Anti-peptic medicines (antacids, antagonists, proton pump inhibitors, sucralfate, and misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant are some of the main medication categories for GI illnesses.

Market Size and Key Findings

The India Gastrointestinal Drugs size is around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.

India Gastrointestinal Drugs Size (In $Bn)

(2021-2030F)

Market Dynamics

Market Growth Drivers Analysis

The majority of countries' ageing populations will fuel the market for gastrointestinal medications. During the projection period, the market's growth will be greatly aided by the expansion of the patient pool brought about by an increase in the world's elderly population. The WHO predicts that one in every six persons on the earth will be 60 or older by the year 2030. By 2050, there will be 2.2 billion people over the age of 60, up from 1 billion in 2020. The ageing of the population raised the need for medical attention and increased healthcare spending. This will result in a rise in the demand for pharmaceutical items, which will have a substantial impact on market expansion throughout this time.

Market Restraints

The global market for gastrointestinal medications has many growth prospects and driving forces, but some constraints are restraining its expansion. The primary reason impeding its expansion is the high cost of raw materials used in the manufacture of gastrointestinal medications. Another issue limiting its expansion is the rise in the use of counterfeit drugs. The market growth for gastrointestinal medications is further constrained by the significant amount spent on research and development.

Competitive Landscape

Key Players

Some of the key companies are Takeda Pharmaceuticals, Bayer AG, Abbott Laboratories, Otsuka Holdings Co ltd, Johnson & Johnson, Reckitt Benckiser Group plc, Bausch Health Companies Inc., Sanofi S.A, Procter & Gamble and Daiichi Sankyo Company.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

India Gastrointestinal Drugs Market Analysis Segmentation

By Type (Revenue, USD Billion):

Antacids
Antiulcerants
Vitamin and Minerals
Antiobesity
Antiemetics and Antinauseants
Antidiarrheals

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies/ Drug Stores
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Drug Classification (Revenue, USD Billion):

Branded Drugs
Generic Drugs

By Mode of Purchase (Revenue, USD Billion):

Prescription-Based Drugs
Over-The-Counter Drugs

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.